Menu
Back to Journals » Neuropsychiatric Disease and Treatment
Neuropsychiatric Disease and Treatment
ISSN: 1178-2021
- View all (4182)
- Volume 20, 2024 (76)
- Volume 19, 2023 (249)
- Volume 18, 2022 (272)
- Volume 17, 2021 (351)
- Volume 16, 2020 (325)
- Volume 15, 2019 (353)
- Volume 14, 2018 (354)
- Volume 13, 2017 (333)
- Volume 12, 2016 (367)
- Volume 11, 2015 (340)
- Volume 10, 2014 (275)
- Volume 9, 2013 (223)
- Volume 8, 2012 (74)
- Volume 7, 2011 (87)
- Volume 6, 2010 (90)
- Volume 5, 2009 (65)
- Volume 4, 2008 (128)
- Volume 3, 2007 (105)
- Volume 2, 2006 (70)
- Volume 1, 2005 (45)
Journal Articles:
- Epileptic disorders: advances in the diagnostic and therapeutic strategies (2)
- The effectiveness of non-pharmacological interventions for people with cognitive dysfunction (1)
- Stroke and neurorestoratology (1)
- Suicide Prevention and Intervention: Recent Evidence and Future Directions (4)
- Family and Peer Facilitated/Led Interventions for Severe Mental Health Problems (2)
- Autism, the disorder without borders and geopolitical variations (3)
- Therapeutic Response to Psychedelic Therapy – Who, What, Why & How? (3)
- Beneath the surface: genetic factors in schizophrenia (2)
- Current Perspectives of Chronic Stress: from Neurobiology to Treatment (3)
- Issues and Solutions in Autism Spectrum Disorders (ASD) (9)
- Cariprazine in schizophrenia (5)
- The Caregiver Perspective on Pediatric ADHD (3)
- Volume 7 - Supplement 1 (5)
- Volume 6 - Supplement 1 (6)
Efficacy of Personalized Postoperative Epilepsy Management in Patients with Glioblastoma Utilizing IDH1 Gene Assessment
Meng GQ, Chen S, Ye HB, Ma BJ, Tao S, Ye Z
Neuropsychiatric Disease and Treatment 2024, 20:855-862
Published Date: 12 April 2024
Neuropsychiatric Symptoms Predict Faster Cognitive Decline in Dementia Collaborative Care Than Antipsychotic Use
Chen YJ, Chang MC, Jhang KM, Wang WF, Liao YC
Neuropsychiatric Disease and Treatment 2024, 20:689-696
Published Date: 26 March 2024
Endovascular Thrombectomy for Acute Ischemic Stroke in Indonesia: Challenging and Strategic Planning
Rilianto B, Kurniawan RG, Rajab NM, Prasetyo BT
Neuropsychiatric Disease and Treatment 2024, 20:621-630
Published Date: 21 March 2024
Validity and Reliability Study of the Turkish Version of the Orbach Mikulincer Mental Pain Scale-8 in a Clinical Population
Demirkol ME, Tamam L, Namlı Z, Yeşiloğlu C, Yılmaz H
Neuropsychiatric Disease and Treatment 2024, 20:429-438
Published Date: 1 March 2024
Hormonal Changes in Women with Epilepsy
Li Q, Zhang Z, Fang J
Neuropsychiatric Disease and Treatment 2024, 20:373-388
Published Date: 26 February 2024
What Do Farmers Need for Suicide Prevention: Considerations for a Hard-to-Reach Population
Scheyett A, Marburger IL, Scarrow A, Hollifield SM, Dunn JW
Neuropsychiatric Disease and Treatment 2024, 20:341-352
Published Date: 22 February 2024
A Thematic Analysis Investigating the Inaugural Psychosis REACH Family Ambassador Peer Training Program
Vaswani-Bye A, McCain C, Blank JM, Tennison ME, Kopelovich SL
Neuropsychiatric Disease and Treatment 2024, 20:233-245
Published Date: 8 February 2024
Excess Mortality in Individuals with Autism Spectrum Disorder: A Population-Based Cohort Study
Huang YH, Wu SI, Lee MJ, Chen YL, Yang YH, Kuo TY, Hung TH, Dewey ME, Stewart R, Chen VCH
Neuropsychiatric Disease and Treatment 2024, 20:247-255
Published Date: 8 February 2024
The Inter-Relationships Between Depressive Symptoms and Suicidality Among Macau Residents After the “Relatively Static Management” COVID-19 Strategy: A Perspective of Network Analysis
Lam MI, Cai H, Chen P, Lok KI, Chow IHI, Si TL, Su Z, Ng CH, An FR, Xiang YT
Neuropsychiatric Disease and Treatment 2024, 20:195-209
Published Date: 3 February 2024
Effect of Object on Kinesthetic Motor Imagery in Autism Spectrum Disorder: A Pilot Study Based on Eye-Tracking Methodology
Liu Y, Hu J
Neuropsychiatric Disease and Treatment 2024, 20:167-183
Published Date: 24 January 2024
Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions
Modlin NL, Creed M, Sarang M, Maggio C, Rucker JJ, Williamson V
Neuropsychiatric Disease and Treatment 2024, 20:109-135
Published Date: 20 January 2024
NR3C1 and NR3C2 Genes Increase the Risk of Suicide Attempt in Psychiatric Disorder Patients with History of Childhood Trauma
Sanabrais-Jiménez MA, Esquivel-López AA, Sotelo-Ramírez CE, Aguilar-García A, Ordoñez-Martínez B, Jiménez-Pavón J, Madrigal-Lara MV, Díaz-Vivanco AJ, Camarena B
Neuropsychiatric Disease and Treatment 2023, 19:2561-2571
Published Date: 24 November 2023
Genetic Susceptibility to Tardive Dyskinesia and Cognitive Impairments in Chinese Han Schizophrenia: Role of Oxidative Stress-Related and Adenosine Receptor Genes
Jiang Q, Zhang X, Lu X, Li Y, Lu C, Chi J, Ma Y, Shi X, Wang L, Li S
Neuropsychiatric Disease and Treatment 2023, 19:2499-2509
Published Date: 20 November 2023
Frozen in Time, a Focused Review of Autism Prevalence in Canadian Indigenous Communities
Hus Y
Neuropsychiatric Disease and Treatment 2023, 19:2451-2468
Published Date: 16 November 2023
Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis
Ko K, Carter B, Cleare AJ, Rucker JJ
Neuropsychiatric Disease and Treatment 2023, 19:2105-2113
Published Date: 5 October 2023
Efficacy of Psychosocial and Psychological Interventions in Addition to Drug Therapy to Improve Global Functioning of Inpatients with Schizophrenia Spectrum and Mood Disorders: A Real-World Observational Study
Chiappini S, Di Carlo F, Mosca A, d'Andrea G, Di Paolo M, Lorenzini C, Lupica MG, Sampogna G, Pettorruso M, Fiorillo A, Martinotti G
Neuropsychiatric Disease and Treatment 2023, 19:1887-1897
Published Date: 30 August 2023
Peripheral Complement Factor-Based Biomarkers for Patients with First-Episode Schizophrenia
Cao Y, Xu Y, Xia Q, Shan F, Liang J
Neuropsychiatric Disease and Treatment 2023, 19:1455-1462
Published Date: 23 June 2023
Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders
Kanes SJ, Dennie L, Perera P
Neuropsychiatric Disease and Treatment 2023, 19:811-828
Published Date: 12 April 2023
Use of Selective Alternative Therapies for Treatment of OCD
Khan I, Jaura TA, Tukruna A, Arif A, Tebha SS, Nasir S, Mukherjee D, Masroor N, Yosufi A
Neuropsychiatric Disease and Treatment 2023, 19:721-732
Published Date: 5 April 2023
Impact of Childhood Adversity, as Early Life Distress, on Cytokine Alterations in Schizophrenia
Miljevic C, Munjiza-Jovanovic A, Jovanovic T
Neuropsychiatric Disease and Treatment 2023, 19:579-586
Published Date: 11 March 2023
Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study
Hurşitoğlu O, Kurutas EB, Strawbridge R, Uygur OF, Yildiz E, Reilly TJ
Neuropsychiatric Disease and Treatment 2022, 18:2519-2527
Published Date: 2 November 2022
Focus on Issues and Solutions in Autism Spectrum Disorders (ASD)
Petinou K, Hus Y, Segal O
Neuropsychiatric Disease and Treatment 2022, 18:2273-2277
Published Date: 17 October 2022
Rehabilitation Services for Young Adults with ASD
Kristofik A, Johnson KL
Neuropsychiatric Disease and Treatment 2022, 18:2361-2366
Published Date: 17 October 2022
The Efficacy of Head-Mounted-Display Virtual Reality Intervention to Improve Life Skills of Individuals with Autism Spectrum Disorders: A Systematic Review
Skjoldborg NM, Bender PK, Jensen de López KM
Neuropsychiatric Disease and Treatment 2022, 18:2295-2310
Published Date: 17 October 2022
Nature and Effects of Autobiographical Memory Issues in Persons with Autism Spectrum Disorders
Westby C
Neuropsychiatric Disease and Treatment 2022, 18:2279-2293
Published Date: 17 October 2022
Recent Advances of Telepractice for Autism Spectrum Disorders in Speech and Language Pathology
Christopoulou M, Drosos K, Petinou K
Neuropsychiatric Disease and Treatment 2022, 18:2379-2389
Published Date: 14 October 2022
Language and Speech Characteristics in Autism
Vogindroukas I, Stankova M, Chelas EN, Proedrou A
Neuropsychiatric Disease and Treatment 2022, 18:2367-2377
Published Date: 14 October 2022
Feeding and Swallowing Issues in Autism Spectrum Disorders
Adams SN
Neuropsychiatric Disease and Treatment 2022, 18:2311-2321
Published Date: 14 October 2022
Comparing Theory of Mind Development in Children with Autism Spectrum Disorder, Developmental Language Disorder, and Typical Development
Schwartz Offek E, Segal O
Neuropsychiatric Disease and Treatment 2022, 18:2349-2359
Published Date: 14 October 2022
Detecting Time Concept Competence in Children with Autism Spectrum and Attention Disorders
Hus Y
Neuropsychiatric Disease and Treatment 2022, 18:2323-2348
Published Date: 14 October 2022
Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series
Bajouco M, Mota D
Neuropsychiatric Disease and Treatment 2022, 18:1351-1362
Published Date: 5 July 2022
Cariprazine in Three Special Different Areas: A Real-World Experience
Gesi C, Paletta S, Palazzo M C, Dell'Osso B, Mencacci C, Cerveri G
Neuropsychiatric Disease and Treatment 2021, 17:3581-3588
Published Date: 7 December 2021
Cariprazine: Patients with Treatment-Resistant Schizophrenia
Aubel T
Neuropsychiatric Disease and Treatment 2021, 17:2327-2332
Published Date: 14 July 2021
Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
Müller HHO, Moeller S
Neuropsychiatric Disease and Treatment 2021, 17:1089-1093
Published Date: 15 April 2021
Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
Montes JM, Montes P, Hernández-Huerta D
Neuropsychiatric Disease and Treatment 2021, 17:291-296
Published Date: 3 February 2021
Access to diagnosis, treatment, and supportive services among pharmacotherapy-treated children/adolescents with ADHD in Europe: data from the Caregiver Perspective on Pediatric ADHD survey
Fridman M, Banaschewski T, Sikirica V, Quintero J, Chen KS
Neuropsychiatric Disease and Treatment 2017, 13:947-958
Published Date: 30 March 2017
Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
Fridman M, Banaschewski T, Sikirica V, Quintero J, Erder MH, Chen KS
Neuropsychiatric Disease and Treatment 2017, 13:443-455
Published Date: 13 February 2017
Factors associated with caregiver burden among pharmacotherapy-treated children/adolescents with ADHD in the Caregiver Perspective on Pediatric ADHD survey in Europe
Fridman M, Banaschewski T, Sikirica V, Quintero J, Erder MH, Chen KS
Neuropsychiatric Disease and Treatment 2017, 13:373-386
Published Date: 7 February 2017
The noradrenergic symptom cluster: clinical expression and neuropharmacology
Blier P, Briley M
Neuropsychiatric Disease and Treatment 2011, 7:15-20
Published Date: 3 June 2011
Improvement of the noradrenergic symptom cluster following treatment with milnacipran
Kasper S, Meshkat D, Kutzelnigg A
Neuropsychiatric Disease and Treatment 2011, 7:21-27
Published Date: 31 May 2011
The importance of norepinephrine in depression
Moret C, Briley M
Neuropsychiatric Disease and Treatment 2011, 7:9-13
Published Date: 31 May 2011
The increasing burden of depression
Lépine J-P, Briley M
Neuropsychiatric Disease and Treatment 2011, 7:3-7
Published Date: 31 May 2011
Noradrenergic symptom cluster in depression
Montgomery S, Briley M
Neuropsychiatric Disease and Treatment 2011, 7:1-2
Published Date: 31 May 2011
Milnacipran: a unique antidepressant?
Siegfried Kasper, Gerald Pail
Neuropsychiatric Disease and Treatment 2010, 6:23-31
Published Date: 25 August 2010
Antidepressant therapy with milnacipran and venlafaxine
Lucilla Mansuy
Neuropsychiatric Disease and Treatment 2010, 6:17-22
Published Date: 25 August 2010
Treatment of patients with comorbid depression and diabetes with metformin and milnacipran
Peter Hofmann
Neuropsychiatric Disease and Treatment 2010, 6:9-15
Published Date: 25 August 2010
Milnacipran: recent findings in depression
Guest editors: Stuart Montgomery (London, UK) and Mike Briley (Castres, France)
Neuropsychiatric Disease and Treatment 2010, 6:0-0
Published Date: 24 August 2010
Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran
Philippe Courtet
Neuropsychiatric Disease and Treatment 2010, 6:3-8
Published Date: 24 August 2010
Editorial Foreword - Milnacipran: recent findings in depression
Stuart Montgomery, Mike Briley
Neuropsychiatric Disease and Treatment 2010, 6:1-2
Published Date: 24 August 2010